# OnCo record trametinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/trametinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "trametinib" ;
  schema:name "Trametinib"@en ;
  schema:description "Trametinib (Mekinist) blocks MEK, the protein one step below BRAF in the growth-signal chain. Paired with dabrafenib it treats BRAF-mutant melanoma, lung, thyroid and other cancers, including brain tumours in children."@en ;
  schema:url <https://onco.cc/drugs/trametinib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Trametinib> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=trametinib>, <https://www.cancer.gov/about-cancer/treatment/drugs/trametinib>, <https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist> ;
  onco:status "approved" ;
  onco:tag "nci-list" ;
  onco:modality "Small-molecule allosteric MEK1/2 inhibitor" ;
  schema:alternateName "Mekinist" ;
  onco:approval "US 2013: BRAF V600E/K unresectable or metastatic melanoma (single agent)", "US 2014: With dabrafenib: metastatic melanoma; later adjuvant melanoma, NSCLC, anaplastic thyroid cancer, tumour-agnostic BRAF V600E solid tumours, paediatric low-grade glioma", "EU 2014: BRAF V600 melanoma alone or with dabrafenib; later NSCLC and adjuvant melanoma" ;
  onco:acceleratedApproval "US 2014-01-08: In combination with dabrafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test", "US 2022-06-22: In combination with dabrafenib for adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options *" ;
  onco:acceleratedApprovalConfirmed "US 2015-11-20: In combination with dabrafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test" ;
  onco:related <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/biomarkers/braf-v600e/> ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/anaplastic-thyroid-cancer/>, <https://onco.cc/cancers/low-grade-serous-ovarian-cancer/>, <https://onco.cc/cancers/paediatric-low-grade-glioma/>, <https://onco.cc/cancers/paediatric-high-grade-glioma/>, <https://onco.cc/cancers/braf-v600e-nsclc/>, <https://onco.cc/cancers/braf-v600-melanoma/>, <https://onco.cc/cancers/stage-iii-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/mek/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:trials <https://onco.cc/trials/combi-ad/>, <https://onco.cc/trials/nct04940052/>, <https://onco.cc/trials/nct05372354/>, <https://onco.cc/trials/nct05358249/>, <https://onco.cc/trials/nct04417621/>, <https://onco.cc/trials/nct03899155/>, <https://onco.cc/trials/nct05874414/> .